CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Propranolol +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01222091
NCT01222091Phase 2Completed

Effect of Beta Blockade on Opioid-Induced Hyperalgesia in Humans

Stanford University·interventional·Posted Oct 18, 2010·Updated Jun 15, 2018

In Brief

A Phase 2 clinical trial evaluating Propranolol, Placebo to Match Propranolol, and 1 other intervention for Hyperalgesia. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This research study explores whether a beta-blocker (propranolol) can prevent a person from becoming more sensitive to pain after administration of an opioid (remifentanil). Beta blockers inhibit the sympathetic (fight or flight) response and are often used to treat angina and high blood pressure. In a previous study in human volunteers, the investigators demonstrated an increased sensitivity to pain after a 60-minute infusion of the opioid remifentanil. The goal of this study is to identify a possible inhibitor of this phenomenon.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperalgesia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 18, 2010
Enrollment StartFeb 1, 2009
Primary CompletionMay 1, 2011
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.7 years ago

Interventions

Propranololdrug

Propranolol administered intravenously, initially set to target plasma concentration of 5 ng/mL, titrated upward in 5 ng/mL intervals until a final concentration of 15 ng/mL is achieved.

Placebo to Match Propranololdrug

Remifentanildrug

Remifentanil administered intravenously at a plasma concentration of 3 ng/mL.